University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Felix Y. Feng, MD

Felix Y. Feng, MD

Associate Professor of Radiation Oncology, Depts. of Urology and Medicine; Vice Chair for Faculty Development and Director of Translational Research, Department of Radiation Oncology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

I am a physician-scientist focused on clinical and translational research aimed at improving outcomes for patients with prostate cancer. My research interests include 1) the discovery of prognostic/predictive biomarkers in prostate cancer and 2) the development of rational approaches of targeted treatment for therapy-resistant disease. My laboratory focuses on sequencing and microarray-based approaches to identify molecular determinants of response from samples from prostate cancer patients treated on clinical trials. In addition, I am co-principal investigator of one of the first biomarker-driven clinical trials for patients with metastatic prostate cancer (NCI 9012; NCT01576172) and oversee a clinic focused on prostate cancer patients.


Stanford University, B.S., 06/1998, Biological Studies
Washington University School of Medicine, M.D., 06/2002, Medicine

Professional Experience

  • 2002-2003
    Intern, Dept of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor MI
  • 2003-2005
    Resident, Dept of Radiology, University of Michigan Medical Center, Ann Arbor, MI
  • 2005-2006
    Post-Doctoral Research Fellow, Dept of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
  • 2006-2010
    Resident, Dept of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
  • 2009-2010
    Chief Resident, Dept of Radiation Oncology, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2010-2016
    Assistant Professor, Dept of Radiation Oncology, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2010-2012
    Assistant Professor, Dept of Radiation Oncology, Ann Arbor Veteran's Health System, Ann Arbor, MI
  • 2010-present
    Leader, the Genitourinary Cancer Translational Research Program for the NRG/RTOG Cooperative Group
  • 2011
    Acting Chief, Radiation Oncology, Dept of Radiation Oncology, Ann Arbor Veteran's Health System, Ann Arbor, MI
  • 2013-2016
    Director, Division of Translational Genomics, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2015-2016
    Associate Chair for Laboratory Research, Dept of Radiation Oncology, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2016-present
    Associate Professor of Radiation Oncology, Urology, and Medicine
  • 2016-present
    Vice Chair for Faculty Development and Translational Research, Dept of Radiation Oncology, University of California at San Francisco, CA

Honors & Awards

  • 1997
    Barry M. Goldwater Fellowship for Excellence in Mathematics, Science, and Engineering
  • 1998-2002
    Dr. Philip Majerus Distinguished Alumni Scholarship
  • 2002
    Dr. Richard S. Brookings Medical School Prize
  • 2008
    American Society of Therapeutic Radiology and Oncology Resident Clinical Research Award
  • 2010
    Radiological Society of North America Roentgen Resident/Fellow Research Award
  • 2012
    American Society of Radiation Oncology Basic Science Award
  • 2014
    Radiobiology Teacher of the Year, Dept of Radiation Oncology, University of Michigan
  • 2016
    American Society of Radiation Oncology Clinical Science Award

Selected Publications

  1. Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf D, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY. DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway. Clin Cancer Res. 2019 Jul 02.
    View on PubMed
  2. Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella LG, Lallas CD, Trabulsi EJ, Feng FY, Filvaroff EH, Hege K, Rathkopf D, Knudsen KE. Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. Clin Cancer Res. 2019 Jul 02.
    View on PubMed
  3. Boreta L, Gadzinski AJ, Hope TA, Feng FY. Author Reply. Urology. 2019 Jul; 129:163-164.
    View on PubMed
  4. Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL. Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019 Jul 01.
    View on PubMed
  5. Rosenthal SA, Hu C, Sartor O, Feng FY, Sandler HM. Reply to J.B. Aragon-Ching. J Clin Oncol. 2019 Jul 01; JCO1901332.
    View on PubMed
  6. Mahal AR, Butler S, Franco I, Muralidhar V, Larios D, Pike LRG, Zhao SG, Sanford NN, Dess RT, Feng FY, D'Amico AV, Spratt DE, Yu JB, Nguyen PL, Rebbeck TR, Mahal BA. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer. 2019 Jun 28.
    View on PubMed
  7. Parolia A, Cieslik M, Chu SC, Xiao L, Ouchi T, Zhang Y, Wang X, Vats P, Cao X, Pitchiaya S, Su F, Wang R, Feng FY, Wu YM, Lonigro RJ, Robinson DR, Chinnaiyan AM. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature. 2019 Jun 26.
    View on PubMed
  8. Alshalalfa M, Nguyen PL, Beltran H, Chen WS, Davicioni E, Zhao SG, Rebbeck TR, Schaeffer EM, Lotan TL, Feng FY, Mahal BA. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. Eur Urol Oncol. 2019 Jun 01.
    View on PubMed
  9. Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med. 2019 05 23; 380(21):2070-2072.
    View on PubMed
  10. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 May 23.
    View on PubMed
  11. Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 May 23.
    View on PubMed
  12. Zhao SG, Yu M, Spratt DE, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR. Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro Oncol. 2019 May 23.
    View on PubMed
  13. Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA. Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers. Mol Cancer Res. 2019 May 20.
    View on PubMed
  14. Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE. The current state of randomized clinical trial evidence for prostate brachytherapy. Urol Oncol. 2019 May 03.
    View on PubMed
  15. Lawhn-Heath C, Flavell RR, Behr SC, Yohannan T, Greene KL, Feng F, Carroll PR, Hope TA. Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer. AJR Am J Roentgenol. 2019 Apr 30; 1-8.
    View on PubMed
  16. Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Apr 22.
    View on PubMed
  17. Jan YJ, Yoon J, Chen JF, Teng PC, Yao N, Cheng S, Lozano A, Chu GCY, Chung H, Lu YT, Chen PJ, Wang JJ, Lee YT, Kim M, Zhu Y, Knudsen BS, Feng FY, Garraway IP, Gao AC, Chung LWK, Freeman MR, You S, Tseng HR, Posadas EM. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Theranostics. 2019; 9(10):2812-2826.
    View on PubMed
  18. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019 Jul 15; 104(4):778-789.
    View on PubMed
  19. Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, Sharp A, Yuan W, Aversa C, Yang XJ, Nelson PS, Feng FY, Chinnaiyan AM, de Bono JS, Morrissey C, Rettig MB, Yu J. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019 May 15; 79(10):2580-2592.
    View on PubMed
  20. Feng FY, Gilbert LA. Lethal clues to cancer-cell vulnerability. Nature. 2019 Apr; 568(7753):463-464.
    View on PubMed

Go to UCSF Profiles, powered by CTSI